The Filing Desk

Varex Imaging

VREX · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

VREX · Last close · November 13, 2026
$18.10
Value Varex Imaging yourself

Varex Imaging's revenue rose 4.1% to $845 million in fiscal 2025. Its operating margin was −3.3%, down from 4.0% a year earlier. Free cash flow was $19 million, down 7.8%. The diluted share count rose 1.5%.

Varex Imaging Corp Latest fiscal year ended October 3, 2025 10-K filed November 18, 2025 · 0001681622-25-000108 Updated
Revenue
$845M
4.1%
Operating margin
−3.3%
7.2 pts
Net income
−$70M
 
Free cash flow
$19M
7.8%
Return on capital
−2.9%
4.9 pts
Market cap
$771M
Nov 13 close
P/E
34.2x
On $0.53 EPS, 4 qtrs

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

About these figures. Net debt to EBITDA for fiscal 2025 is blank: the 10-K's structured data doesn't include every figure it needs.

Charts show fiscal years, from the 10-K filings.

What Varex Imaging does

Varex Imaging makes X-ray imaging components. It sells them mostly to equipment makers, called OEMs, which build the parts into their own X-ray systems. The company says a substantial majority of medical X-ray OEMs are its customers, and that many have been customers for over 35 years.

It has two reportable segments. The Medical segment designs, makes, sells and services X-ray tubes, flat panel and photon counting detectors, high voltage connectors, software, generators and other parts. These are used in imaging such as CT, mammography, cardiac, dental and fluoroscopy. The Industrial segment supplies components for security and cargo screening, industrial quality inspection, and analysis and measurement in manufacturing.

Varex sells in three regions: the Americas, EMEA (Europe, the Middle East, India and Africa) and APAC. It says it is one of the largest independent X-ray imaging component suppliers. It has engineering, manufacturing and service sites in North America, Europe and Asia. It says it competes in highly competitive industries with pricing pressure, and that some of its OEM customers are also its competitors.

Its biggest risks, as it describes them

  • Tariffs and changes in import and export rules, including those affecting its sales to China.
  • Selling to a limited number of OEM customers, many of which are also competitors.
  • Customer order forecasts that change often, making demand hard to predict.
  • Strong competition and pricing pressure in its industries.
  • New generations of products that may not be developed or sold successfully.
From Varex Imaging's annual report on Form 10-K, filed November 18, 2025, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

From fiscal 2016 to 2023, earnings per share fell 7.3% a year and net income 5.1% a year, as new shares raised the share count by 33% and diluted each share's earnings. Varex Imaging then lost money in fiscal 2024 and 2025.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments14589194200155
Debt incl. finance leases435415443450374
Net debt (negative means net cash)290325249249218
Net debt to EBITDA2.6x2.7x2.3x3.9x—
Debt to equity0.9x0.8x0.8x0.8x0.8x
Interest coverage1.8x2.2x2.6x1.1x−0.8x
Current ratio3.3x3.5x4.0x3.3x3.4x
Quick ratio2.0x1.8x2.3x2.0x1.8x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Varex Imaging's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

No officer, director or 10% owner of Varex Imaging reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.

From Form 4 filings with the SEC. Grants, option exercises and shares withheld for tax aren't counted. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score6 of 94 of 96 of 9
Rule of 4013.8%−6.7%6.4%
Altman Z''4.233.663.33
Accruals ratio−5.0%−7.8%−9.7%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positivePassFailFail
Cash from operations is positivePassPassPass
Return on assets rosePassFailFail
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsFailPassPass
Current ratio rosePassFailPass
Share count didn't riseFailPassFail
Gross margin roseFailFailPass
Revenue rose relative to assetsPassFailPass
F-score6 of 94 of 96 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put Varex Imaging side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Varex ImagingFY254.1%−3.3%2.2%−2.9%—6
Inspire Medical SystemsFY2513.6%5.6%8.6%14.2%−4.8x5Compare
AlphatecFY2524.9%−10.8%0.4%−14.3%—5Compare
iRhythmFY2526.2%−7.7%4.6%−12.4%—5Compare
Tandem Diabetes CareFY257.9%−18.4%−2.9%−85.5%—4Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue620698773781738818859893811845
Revenue growth−1.9%12.6%10.8%0.9%−5.4%10.8%5.0%4.0%−9.2%4.1%
Gross profit248254254257190272284290257290
Research and development54678378797277858791
Operating income109844446−3474887732−28
Net income68522816−58173047−49−70
Diluted EPS (US$)1.821.360.720.40−1.490.430.731.07−1.20−1.70
Diluted shares (millions)38383839394042504141
Cash flow
Cash from operations747585721393171084742
Capital expenditure29202020241521212723
Free cash flow45556552−1078−4882019
Dividends paid0000000000
Share buybacks0000000000
Acquisitions1272570200110
Stock-based compensation1081012131414141515
Balance sheet at fiscal year end
Cash and short-term investments3683523010114589194200155
Debt incl. finance leases0484390395456435415443450374
Total assets6221,0409881,0391,1401,1481,1841,2501,2141,107
Total liabilities86650548580674651638669670621
Shareholders' equity526379426445452483533568529473
Margins and ratios
Gross margin40.1%36.3%32.8%32.9%25.8%33.2%33.0%32.5%31.7%34.4%
Operating margin17.6%12.0%5.8%5.8%−4.6%9.1%10.3%8.6%4.0%−3.3%
Net margin11.1%7.4%3.6%2.0%−7.8%2.1%3.5%5.3%−6.0%−8.3%
Free cash flow margin7.3%7.9%8.4%6.7%−1.4%9.5%−0.5%9.8%2.5%2.2%
Rule of 40 (growth + FCF margin)5.4%20.5%19.2%7.6%−6.8%20.3%4.5%13.8%−6.7%6.4%
Return on capital—9.2%5.8%4.2%−3.3%5.8%7.4%9.1%2.0%−2.9%
Return on equity—11.4%6.8%3.6%−12.9%3.7%6.0%8.6%−8.9%−14.0%
Return on assets—6.2%2.7%1.5%−5.3%1.5%2.6%3.9%−4.0%−6.1%
Net debt to EBITDA−0.3x3.6x3.9x4.3x61.3x2.6x2.7x2.3x3.9x—
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Varex Imaging's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Varex Imaging.